Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anser anser feather extract is a non-standardized allergenic product derived from the feathers of the greylag goose. [1-1] It is labeled by Greer Laboratories, Inc. and marketed under the brand name "Goose Feathers". [1-1, 1-2] The extract is available as a solution at a concentration of 0.05 g/mL for diagnostic and therapeutic use. [1-1, 1-3, 7] Its primary indication is for the in vivo diagnosis of allergies to goose feathers through skin testing (percutaneous or intradermal). [2, 7] In sensitized individuals, application of the extract triggers a localized allergic reaction. It is also indicated for use in allergen immunotherapy (hyposensitization) to reduce allergic symptoms in patients with confirmed sensitivity. [4, 7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anser anser feather extract.